nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00005095,Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study,,Recruiting,Observational,"Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Sarcoma; Uterine Leiomyomata; Vaginal Cancer; Vulvar Cancer",Ca-125; screening questionnaire administration; Surgery,,Northwestern University,National Cancer Institute (NCI),6000,2000-03-05,2040-12-05,United States,No,https://clinicaltrials.gov/study/NCT00005095
NCT01109394,Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies,,Recruiting,Observational,Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer,,,National Cancer Institute (NCI),,6035,2010-04-21,,United States,No,https://clinicaltrials.gov/study/NCT01109394
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02792270,Effects Of Caloric Restriction On Post-Operative Complications In Sarcoma Patients Treated With Pre-Operative Radiation Therapy,Not Applicable,Recruiting,Interventional,Tumor Surgery,Caloric Restriction Diet,,Massachusetts General Hospital,,32,2016-06-05,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT02792270
NCT03076658,Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers,Not Applicable,Recruiting,Interventional,"Intervertebral Disc Degeneration; Osteoarthritis, Spine",EOS imaging,,"University of Colorado, Denver",,60,2016-09-05,2031-01-05,United States,No,https://clinicaltrials.gov/study/NCT03076658
NCT03141021,Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors,,Recruiting,Observational,Malignant Peripheral Nerve Sheath Tumors,,,Washington University School of Medicine,Boston's Children Hospital,1050,2017-04-28,2053-04-30,Canada; India; Japan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03141021
NCT03300830,"Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease",,Recruiting,Observational,Human Immunodeficiency Virus; Castleman's Disease; Kaposi's Sarcoma; Viral-Associated Cancer,,,National Cancer Institute (NCI),,280,2017-12-20,2037-06-25,United States,No,https://clinicaltrials.gov/study/NCT03300830
NCT03420963,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,Phase 1,Recruiting,Interventional,Recurrent Cutaneous Melanoma; Recurrent Lip and Oral Cavity Carcinoma; Recurrent Malignant Endocrine Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Male Reproductive System Neoplasm; Recurrent Malignant Mesothelioma; Recurrent Malignant Neoplasm of Multiple Primary Sites; Recurrent Malignant Oral Neoplasm; Recurrent Malignant Pharyngeal Neoplasm; Recurrent Malignant Skin Neoplasm; Recurrent Malignant Soft Tissue Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Thyroid Gland Neoplasm; Recurrent Malignant Urinary System Neoplasm; Refractory Cutaneous Melanoma; Refractory Malignant Bone Neoplasm; Refractory Malignant Endocrine Neoplasm; Refractory Malignant Female Reproductive System Neoplasm; Refractory Malignant Male Reproductive System Neoplasm; Refractory Malignant Mesothelioma; Refractory Malignant Neoplasm of Multiple Primary Sites; Refractory Malignant Oral Neoplasm; Refractory Malignant Pharyngeal Neoplasm; Refractory Malignant Skin Neoplasm; Refractory Malignant Soft Tissue Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Malignant Thyroid Gland Neoplasm; Refractory Malignant Urinary System Neoplasm,Cord Blood-derived Expanded Allogeneic Natural Killer Cells; Cyclophosphamide; Etoposide,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),38,2018-08-31,2027-12-01,United States,No,https://clinicaltrials.gov/study/NCT03420963
NCT03739827,Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors,,Recruiting,Observational,Malignant Solid Tumors; Other Neoplasms Solid Tumors; Pediatric Solid Tumor; Refractory Solid Tumors; Solid Tumor,,,National Cancer Institute (NCI),,10000,2019-01-28,2032-03-31,United States,No,https://clinicaltrials.gov/study/NCT03739827
NCT03968393,Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative Atrial Fibrillation After Noncardiac Surgery - The ASPIRE-AF Trial,Phase 4,Recruiting,Interventional,Stroke; Atrial Fibrillation,Non-vitamin K oral anticoagulant (NOAC),,Population Health Research Institute,Hamilton Health Sciences Corporation,2270,2019-06-14,2028-12-05,Argentina; Australia; Brazil; Canada; Denmark; Finland; Germany; India; Italy; Nepal; Netherlands; Pakistan; South Korea; Spain; Sweden; Switzerland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03968393
NCT04087902,A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery,,Recruiting,Observational,Pituitary Tumor; Meningioma; Rathke Cleft Cysts; Chordoma; Chondrosarcoma; Craniopharyngioma; Encephalocele; Esthesioneuroblastoma,,,Ohio State University,,400,2019-07-16,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04087902
NCT04123535,Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma,Not Applicable,Recruiting,Interventional,Undifferentiated Pleomorphic Sarcoma,ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS),,Matthew Bucknor,Focused Ultrasound Foundation; InSightec-TxSonics,20,2020-01-23,2026-06-30,United States,No,https://clinicaltrials.gov/study/NCT04123535
NCT04130503,The Recovery in Stroke Using PAP Study,Not Applicable,Recruiting,Interventional,Ischemic Stroke; Obstructive Sleep Apnea,PAP; HLE,,Yale University,Hartford HealthCare; National Institute of Nursing Research (NINR); American Academy of Sleep Medicine Foundation (AASM),360,2019-09-01,2025-10-05,United States,No,https://clinicaltrials.gov/study/NCT04130503
NCT04222413,"First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor; Advanced Breast Cancer; Malignant Peripheral Nerve Sheath Tumor; Colorectal Neoplasms,Metarrestin,,National Cancer Institute (NCI),,116,2020-10-27,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT04222413
NCT04256018,"A Phase 2 Single Center, Single Arm, Open Label Mogamulizumab Combined Upfront With Low Dose Total Skin Electron Beam Therapy (LD TSEBT) in Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS)",Phase 2,Recruiting,Interventional,Sezary Syndrome; Mycosis Fungoides,Mogamulizumab; LD TSEBT,,Stanford University,,30,2020-03-30,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT04256018
NCT04282044,A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies,Phase 1,Recruiting,Interventional,"Solid Tumor, Adult; Triple Negative Breast Cancer; Colorectal Cancer; Hepatocellular Carcinoma; Osteosarcoma; Epithelial Ovarian Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Malignant Melanoma",CRX100 suspension for infusion; Fludarabine; Cyclophosphamide,,BioEclipse Therapeutics,,60,2021-01-08,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04282044
NCT04390737,"A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,FL Lymphoma; Epithelioid Sarcoma; Peripheral T Cell Lymphoma; Advanced Solid Tumor,HH2853 Tablets,,"Haihe Biopharma Co., Ltd.",,254,2020-09-08,2025-12-31,China; United States,No,https://clinicaltrials.gov/study/NCT04390737
NCT04458584,Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART),,Recruiting,Observational,Osteoarthritis Thumb,Trapeziectomy with ligament reconstruction (I; LRTI); Trapeziectomy with suture suspensionplasty (II; SS); Arthroscopic Trapeziectomy (III; AT),,Dartmouth-Hitchcock Medical Center,,165,2020-06-29,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04458584
NCT04461171,Enhanced Recovery After Surgery in Extremity Sarcoma,Not Applicable,Recruiting,Interventional,Sarcoma,Enhanced Recovery After Surgery,,Joshua Lawrenz,,120,2020-12-14,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT04461171
NCT04771130,"A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm,BGB-11417; Azacitidine; Posaconazole; BGB-11417; BGB-11417,,BeiGene,,260,2021-05-24,2028-02-08,Australia; China; France; Germany; Italy; New Zealand; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04771130
NCT04797767,"A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms",Phase 1/Phase 2,Recruiting,Interventional,Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; Myeloid Neoplasm; Relapsed Acute Biphenotypic Leukemia; Relapsed Acute Myeloid Leukemia; Relapsed Mixed Phenotype Acute Leukemia; Relapsed Myeloid Neoplasm; Refractory Acute Biphenotypic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myeloid Neoplasm; Recurrent Myeloid Sarcoma,Cladribine; Cytarabine; Mitoxantrone; Recombinant Granulocyte Colony-Stimulating Factor; Venetoclax; Bone Marrow Aspiration; Bone Marrow Biopsy; Biospecimen Collection,,University of Washington,AbbVie,62,2022-02-04,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04797767
NCT04800484,The Effects of AFO Heel Height and Stiffness on Gait,Not Applicable,Recruiting,Interventional,Musculoskeletal Injury; Musculoskeletal Diseases; Peripheral Nervous System Diseases,Tall Soft; Tall Firm; Short Soft; Short Firm,,University of Iowa,,40,2019-11-07,2027-01-01,United States,No,https://clinicaltrials.gov/study/NCT04800484
NCT04858256,"Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms",Phase 2,Recruiting,Interventional,T-Cell Neoplasm; Lymphoproliferative Disorders,Pacritinib,,University of Michigan Rogel Cancer Center,National Institutes of Health (NIH); National Cancer Institute (NCI); Hoosier Cancer Research Network; CTI BioPharma,100,2023-03-29,2028-11-05,United States,No,https://clinicaltrials.gov/study/NCT04858256
NCT04889716,Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas,Phase 2,Recruiting,Interventional,Large B-cell Lymphoma; DLBCL - Diffuse Large B Cell Lymphoma,mosunetuzumab; glofitamab; obinutuzumab,,Abramson Cancer Center at Penn Medicine,"Genentech, Inc.",42,2021-11-05,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT04889716
NCT04890093,Phase 1/2 Study of Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,"Sarcoma, Ewing; Rhabdomyosarcoma",PEN-866; Vincristine; Temozolomide,,National Cancer Institute (NCI),,64,2024-10-31,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04890093
NCT04901702,A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma,Phase 1/Phase 2,Recruiting,Interventional,Recurrent Solid Tumor; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Wilms Tumor; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma,Onivyde; Talazoparib; Temozolomide,,St. Jude Children's Research Hospital,Pfizer; Ipsen,90,2021-06-09,2025-12-31,Canada; United States,No,https://clinicaltrials.gov/study/NCT04901702
NCT04939610,"LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,68Ga-FAP-2286; 177Lu-FAP-2286,,Novartis Pharmaceuticals,,222,2021-07-30,2028-06-30,Australia; Canada; France; Italy; United States,No,https://clinicaltrials.gov/study/NCT04939610
NCT04995003,Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0),Phase 1,Recruiting,Interventional,Sarcoma; HER-2 Protein Overexpression; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma; Synovial Sarcoma; Soft Tissue Sarcoma; Undifferentiated Sarcoma,T cells or CAR T cells; Pembrolizumab Injectable Product; Nivolumab Injectable Product,,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation; National Cancer Institute (NCI)",25,2021-12-07,2040-12-31,United States,No,https://clinicaltrials.gov/study/NCT04995003
NCT05033288,"Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone",,Recruiting,Observational,Bone Sarcoma; Chondrosarcoma; Chordoma; Ewing Sarcoma of Bone; Pelvic Rhabdomyosarcoma,Electronic Health Record Review; Quality-of-Life Assessment,,Mayo Clinic,,72,2022-01-20,2028-08-30,United States,No,https://clinicaltrials.gov/study/NCT05033288
NCT05054335,CPRIT: Optimizing Surgical and Rehabilitation Treatment of Pelvic Sarcomas Using Computational Models,Not Applicable,Recruiting,Interventional,Pelvic Sarcoma,Functional Assessment; X-Ray Imaging,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),130,2019-06-20,2027-12-21,United States,No,https://clinicaltrials.gov/study/NCT05054335
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,MK-1084; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil,,Merck Sharp & Dohme LLC,,830,2021-12-17,2030-02-25,Australia; Canada; Chile; China; Denmark; Israel; Italy; Japan; Lithuania; Malaysia; New Zealand; Panama; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05067283
NCT05068583,Liquid Biopsies in Non-CNS Malignant Pediatric Solid Tumors,,Recruiting,Observational,"Pediatric Solid Tumor, Unspecified, Protocol Specific",Blood Draw,,Children's Hospital Los Angeles,,320,2019-05-08,2034-05-08,United States,No,https://clinicaltrials.gov/study/NCT05068583
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05227326,First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors,Phase 1,Recruiting,Interventional,Refractory Malignant Solid Neoplasm; Osteosarcoma; Leiomyosarcomas; Synovial Sarcomas; Ovarian Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer,PCNA Inhibitor AOH1996,,City of Hope Medical Center,National Cancer Institute (NCI),92,2022-08-12,2029-09-13,United States,No,https://clinicaltrials.gov/study/NCT05227326
NCT05235165,A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma,Phase 3,Recruiting,Interventional,Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Osteosarcoma,Biospecimen Collection; Computed Tomography; Questionnaire Administration; Thoracoscopy; Thoracotomy,,Children's Oncology Group,National Cancer Institute (NCI),250,2022-04-01,2031-03-31,Australia; Canada; New Zealand; Puerto Rico; Saudi Arabia; United States,No,https://clinicaltrials.gov/study/NCT05235165
NCT05313191,Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors,Not Applicable,Recruiting,Interventional,CNS Cancer; Head and Neck Cancer; GI Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; Breast Cancer,Pencil Beam Scanning Proton Therapy,,The New York Proton Center,,1800,2022-01-24,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05313191
NCT05335421,The Influence of Mindfulness on Patient-Reported Outcomes Following Hip Preservation Surgery,Not Applicable,Enrolling by invitation,Interventional,Hip Preservation Surgery,Healthy Minds Program (HMP) App,,"University of Wisconsin, Madison",,200,2021-10-01,2026-04-05,United States,No,https://clinicaltrials.gov/study/NCT05335421
NCT05366881,"cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse",,Recruiting,Observational,Brain Cancer; Breast Cancer; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Esophageal Cancer; Stomach Cancer; Head and Neck Cancer; Hepatobiliary Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer; Sarcoma; Thyroid Cancer,,,"Adela, Inc",,7000,2022-05-03,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05366881
NCT05417594,"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies,AZD9574; Temozolomide (TMZ); [11C]AZ1419 3391; Trastuzumab Deruxtecan (T-DXd); Datopotamab Deruxtecan (Dato-DXd),,AstraZeneca,,695,2022-06-24,2027-08-11,Australia; Germany; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05417594
NCT05429632,"Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT",Phase 3,Recruiting,Interventional,Adult Acute Myeloid Leukemia,mocravimod,,Priothera SAS,,366,2022-06-16,2029-11-05,Argentina; Brazil; France; Germany; Israel; Italy; Japan; Poland; Romania; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05429632
NCT05544019,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies",Phase 1,Recruiting,Interventional,"Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma",SGR-1505,,"Schrödinger, Inc.",,52,2023-04-10,2026-03-05,France; Italy; Moldova; Poland; Romania; Spain; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05544019
NCT05588648,"A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma",Phase 1/Phase 2,Recruiting,Interventional,Osteosarcoma,Vactosertib,,"MedPacto, Inc.",,48,2023-05-01,2025-12-05,South Korea; United States,No,https://clinicaltrials.gov/study/NCT05588648
NCT05607095,"A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma",Phase 1,Recruiting,Interventional,Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma,Lifileucel (LN-144/LN-145),,Memorial Sloan Kettering Cancer Center,"Iovance Biotherapeutics, Inc.",20,2022-11-01,2026-05-01,United States,No,https://clinicaltrials.gov/study/NCT05607095
NCT05642455,"A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors",Phase 1/Phase 2,Recruiting,Interventional,Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcoma,Afamitresgene autoleucel,,Adaptimmune,,20,2023-09-01,2038-07-30,United States,No,https://clinicaltrials.gov/study/NCT05642455
NCT05651945,Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors,Not Applicable,Recruiting,Interventional,Stroke; Cerebrovascular Accident,Cardiac rehabilitation program,,Hackensack Meridian Health,The Cardiovascular Institute of New Jersey at Rutgers Robert Wood Johnson Medical School,150,2023-01-20,2031-01-20,United States,No,https://clinicaltrials.gov/study/NCT05651945
NCT05653388,Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy,,Recruiting,Observational,Leiomyosarcoma,Plasma Collection,,University of Michigan Rogel Cancer Center,National Cancer Institute (NCI),200,2022-12-22,2026-12-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT05653388
NCT05697874,International Rare Brain Tumor Registry,,Recruiting,Observational,"Astroblastoma; BCOR ITD Sarcoma; CNS Sarcoma; Unclassified Tumor, Malignant",,,Children's National Research Institute,,5800,2023-01-01,2033-12-05,United States,No,https://clinicaltrials.gov/study/NCT05697874
NCT05711615,A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas,Phase 1,Recruiting,Interventional,Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Myxofibrosarcoma; Metastatic Sarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Unresectable Dedifferentiated Liposarcoma; Unresectable Leiomyosarcoma; Unresectable Myxofibrosarcoma; Unresectable Sarcoma; Unresectable Synovial Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Pegylated Liposomal Doxorubicin Hydrochloride; Peposertib,,National Cancer Institute (NCI),,30,2024-02-06,2026-05-03,United States,No,https://clinicaltrials.gov/study/NCT05711615
NCT05730036,"An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)",Phase 3,Recruiting,Interventional,Relapsed Refractory Multiple Myeloma (RRMM),Linvoseltamab; Elotuzumab; Pomalidomide; Dexamethasone,,Regeneron Pharmaceuticals,,410,2023-09-18,2033-04-19,Australia; Belgium; Brazil; Canada; Chile; France; Germany; Israel; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05730036
NCT05743426,Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies,,Recruiting,Observational,Sarcoma; Gastrointestinal Cancer,Survey; Toxicity Assessments,,UNC Lineberger Comprehensive Cancer Center,,180,2023-03-17,2036-01-01,United States,No,https://clinicaltrials.gov/study/NCT05743426
NCT05767658,Support Via Online Social Networks to Promote Safe Infant Care Practices Toward Reducing Racial Disparities in Infant Mortality,Not Applicable,Recruiting,Interventional,Breastfeeding; Infant Death; Sudden Infant Death Syndrome Without Mention of Autopsy,Safe Sleep; Breastfeeding; Early Brain Development and Parent-Child Relationships,,University of Virginia,Boston University; Washington University School of Medicine; Boston Medical Center; University of Kentucky; National Institute on Minority Health and Health Disparities (NIMHD),3000,2024-03-01,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT05767658
NCT05806164,Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence,Phase 4,Recruiting,Interventional,Urgency Urinary Incontinence,"Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]; OnabotulinumtoxinA 100 UNT [Botox]",,Women and Infants Hospital of Rhode Island,"University of New Mexico; University of Alabama at Birmingham; University of California, San Diego; Howard University; Brown University; Patient-Centered Outcomes Research Institute",432,2023-06-06,2030-08-01,United States,No,https://clinicaltrials.gov/study/NCT05806164
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05904093,A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease,Phase 1,Recruiting,Interventional,Sickle Cell Disease; Hb-SS Disease; Hemoglobin S; Disease Sickle Cell Anemia; Sickle Cell Disorders; Hemoglobin Beta Thalassemia Disease,Fostamatinib,,"National Heart, Lung, and Blood Institute (NHLBI)",,25,2024-12-18,2026-05-14,United States,No,https://clinicaltrials.gov/study/NCT05904093
NCT05910307,Synovial Sarcoma Registry and Biospecimen Repository,,Recruiting,Observational,Synovial Sarcoma,,,Children's Hospital of Philadelphia,,1000,2023-06-12,2033-06-05,United States,No,https://clinicaltrials.gov/study/NCT05910307
NCT05941039,Effects of Vestibular Training on Postural Control of Healthy Adults Using Virtual Reality,Not Applicable,Recruiting,Interventional,Virtual Reality; Vestibular Training; Balance Assessment,Vestibular training using VR followed by Control; Control followed by Vestibular training using VR,,Clarkson University,Temple University,30,2022-10-03,2025-08-30,United States,No,https://clinicaltrials.gov/study/NCT05941039
NCT05958316,A Randomized Controlled Trial Using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer,Not Applicable,Recruiting,Interventional,Symptoms and Signs; Cancer; Childhood Cancer,Computerized Symptom Capture Tool (C-SCAT) Intervention; Usual Care Control,,Virginia Commonwealth University,National Cancer Institute (NCI),126,2024-01-04,2026-08-31,United States,No,https://clinicaltrials.gov/study/NCT05958316
NCT05999994,CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research,Phase 2,Recruiting,Interventional,Neoplasms; Child; Adolescent,Ramucirumab; Cyclophosphamide; Vinorelbine; Gemcitabine; Docetaxel; Abemaciclib; Irinotecan; Temozolomide,,Eli Lilly and Company,,105,2020-01-22,2027-05-05,Australia; Belgium; France; Germany; Italy; Japan; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05999994
NCT06021626,"A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Malignant Solid Tumors",Phase 1,Recruiting,Interventional,Sarcoma; Merkel Cell Carcinoma,CRD3874,,Memorial Sloan Kettering Cancer Center,Curadev Pharma,72,2023-08-25,2029-08-05,United States,No,https://clinicaltrials.gov/study/NCT06021626
NCT06054555,"A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma",Phase 3,Recruiting,Interventional,Melanoma,ABP 206; Nivolumab,,Amgen,,620,2023-11-02,2028-01-25,Argentina; Bosnia and Herzegovina; Canada; Chile; Croatia; Czechia; Estonia; France; Georgia; Germany; Italy; Jordan; Lebanon; Lithuania; Malaysia; Mexico; Moldova; Netherlands; Philippines; Portugal; Romania; Serbia; South Africa; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); Ukraine; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06054555
NCT06056323,"A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult",HB0045 Drug Product,,"Shanghai Huaota Biopharmaceutical Co., Ltd.",Gabrail Cancer Center Research; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center,71,2023-07-18,2026-03-19,United States,No,https://clinicaltrials.gov/study/NCT06056323
NCT06072131,"A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma",Phase 3,Recruiting,Interventional,Peripheral T Cell Lymphoma,Belinostat Injection; Pralatrexate Injection; CHOP; COP,,Acrotech Biopharma Inc.,,504,2023-10-04,2030-11-05,Canada; Germany; Hungary; Italy; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06072131
NCT06079879,"A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea",Phase 3,Recruiting,Interventional,Essential Thrombocythemia,Bomedemstat; Anagrelide; Busulfan; Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b; Ruxolitinib,,Merck Sharp & Dohme LLC,,340,2023-12-31,2028-08-18,Argentina; Australia; Belgium; Canada; China; Colombia; France; Germany; Hong Kong; Hungary; Israel; Italy; Japan; Netherlands; New Zealand; Poland; Portugal; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06079879
NCT06083883,Phase I/Ib Study of Adoptive NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Reactive Against the NY-ESO-1-specific Cord Blood-derived NK Cells (NY-ESO-1 TCR/IL-15 NK) in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma,Phase 1,Recruiting,Interventional,Synovial Sarcoma; Myxoid/Round Cell Liposarcoma,Fludarabine phosphate; NY-ESO-1 TCR/IL-15 NK; Cyclophosphamide,,M.D. Anderson Cancer Center,,44,2024-03-27,2028-11-30,United States,No,https://clinicaltrials.gov/study/NCT06083883
NCT06242470,"A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Cancer; Metastatic Cancer; Squamous Cell Carcinoma of Head and Neck; Non Small Cell Lung Cancer; Small-cell Lung Cancer; Bladder Cancer; Sarcoma; Endometrial Cancer; Melanoma; Castration Resistant Prostatic Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Gastro-esophageal Cancer; Pancreas Cancer; Clear Cell Renal Cell Carcinoma; Hepatocellular Carcinoma; Platinum-resistant Ovarian Cancer; Breast Cancer; Ovarian Cancer; Esophageal Squamous Cell Cancer (SCC),MGC026 Dose Escalation; MGC026 Dose for Expansion,,MacroGenics,,250,2024-03-06,2028-10-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06242470
NCT06283472,Enhancing Prospective Thinking in Early Recovery,Not Applicable,Recruiting,Interventional,Alcohol Use Disorder,High-Intensity Cue; Low-Intensity Cue,,Indiana University,,21,2024-06-17,2027-12-20,United States,No,https://clinicaltrials.gov/study/NCT06283472
NCT06290141,"A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy",Phase 3,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyneuropathy,riliprubart; Placebo; riliprubart; Placebo; IVIg; Placebo,,Sanofi,,160,2024-08-21,2029-01-12,Argentina; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Hungary; Israel; Japan; Mexico; Portugal; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06290141
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06351631,"A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study",Phase 3,Recruiting,Interventional,"Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera",Bomedemstat,,Merck Sharp & Dohme LLC,,400,2024-05-23,2034-12-04,Australia; Hong Kong; Italy; New Zealand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06351631
NCT06359574,Development and Implementation of a Self-Directed Violence (SDV) Prevention Training Program for the North Carolina Department of Adult Corrections,Not Applicable,Enrolling by invitation,Interventional,"Knowledge, Attitudes, Practice",Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training,,"University of North Carolina, Charlotte",North Carolina Department of Adult Corrections; North Carolina Department of Health and Human Services,100,2024-04-05,2025-01-30,United States,No,https://clinicaltrials.gov/study/NCT06359574
NCT06371768,Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors,Not Applicable,Recruiting,Interventional,Cancer; Breast Cancer; Colorectal Cancer; Sarcoma; Lymphoma; Testicular Cancer,AYA Educational Information; AYA STEPS,,Duke University,National Cancer Institute (NCI),260,2025-07-14,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06371768
NCT06409013,Sarcoma Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography,,Recruiting,Observational,Bone Sarcoma; Soft Tissue Sarcoma,Non-Interventional Study,,Mayo Clinic,,50,2024-03-14,2027-03-30,United States,No,https://clinicaltrials.gov/study/NCT06409013
NCT06421350,Efficacy of Closed-Loop Spinal Cord Stimulation for Complex Regional Pain Syndrome,Not Applicable,Recruiting,Interventional,Complex Regional Pain Syndromes,Spinal Cord Stimulation Device,,Scripps Health,,32,2024-09-03,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06421350
NCT06492954,Phase 1b Trial of Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery in Patients With Pulmonary Recurrence of Osteosarcoma,Phase 1,Recruiting,Interventional,Osteosarcoma; Pulmonary Recurrence of Osteosarcoma,Surgical Resection; Stereotactic Body Radiation Therapy (SBRT); Atezolizumab,,Emory University,"Genentech, Inc.",12,2026-01-05,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06492954
NCT06524635,A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis,Phase 2,Recruiting,Interventional,Hidradenitis Suppurativa; Atopic Dermatitis,Lutikizumab,,AbbVie,,60,2024-08-14,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT06524635
NCT06551987,Cognitive Behavioral Therapy for Insomnia vs Brief Behavioral Therapy for Insomnia in Military Personnel With Postconcussive Symptoms Following Mild Traumatic Brain Injury,Not Applicable,Recruiting,Interventional,Insomnia; Mild Traumatic Brain Injury,Cognitive Behavioral Therapy for Insomnia; Brief Behavioral Therapy for Insomnia,,The University of Texas Health Science Center at San Antonio,Congressionally Directed Medical Research Programs; Hope Health Research Institute,160,2024-12-03,2027-09-01,United States,No,https://clinicaltrials.gov/study/NCT06551987
NCT06564948,Improving Mental Health Treatment for Individuals in Crisis Interacting with the Criminal Justice System,Not Applicable,Recruiting,Interventional,Suicide Risk; Psychiatric Disorders,Treatment as usual (TAU); Family and Social Justice; Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention,,Cambridge Health Alliance,Michigan State University; Mount Auburn Hospital,1040,2025-02-01,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT06564948
NCT06598189,"Real-time Seizure Detection, Classification, and Prediction Using a Low-Cost Low-Burden Ear-worn System",Not Applicable,Recruiting,Interventional,Seizures; Epilepsy,Ear-SD; Electroencephalogram,,Felicia Chu,"University of Massachusetts, Amherst",40,2025-04-03,2032-12-05,United States,No,https://clinicaltrials.gov/study/NCT06598189
NCT06625190,"Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Neuroblastoma; Rhabdomyosarcoma; Synovial Sarcoma; Peripheral Nerve Sheath Tumors; Clear Cell Sarcoma; Alveolar Soft Part Sarcoma; Desmoplastic Small Round Cell Tumor; Chordoma; Rhabdoid Tumor; Epithelioid Sarcoma; Myoepithelial Tumor; Osteosarcoma; Ewing Sarcoma,Miltenyi CliniMACS Prodigy ® system; Zoledronic acid,,University of Florida,,27,2026-02-05,2030-02-05,United States,No,https://clinicaltrials.gov/study/NCT06625190
NCT06630325,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT),Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8,Abemaciclib; Biopsy; Bone Scan; Carboplatin; Echocardiography; Exemestane; Fulvestrant; Gefitinib; Gemcitabine; Letrozole; Multigated Acquisition Scan; Olaparib; Osimertinib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride; Pemetrexed; Survey Administration; Tamoxifen; Temozolomide; Biospecimen Collection,,OHSU Knight Cancer Institute,Oregon Health and Science University; Eli Lilly and Company; AstraZeneca,30,2025-06-24,2033-06-30,United States,No,https://clinicaltrials.gov/study/NCT06630325
NCT06644755,"Phase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors; Sarcoma,DS-2243a,,Daiichi Sankyo,,150,2024-11-14,2028-11-30,Belgium; France; Netherlands; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06644755
NCT06661915,A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs),Phase 2,Recruiting,Interventional,"Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis",Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Iadademstat,,National Cancer Institute (NCI),,62,2025-08-14,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06661915
NCT06722755,Optimizing Adherence to the Treatment of Sleep Apnea Among Patients With Stroke Undergoing Inpatient Rehabilitation,Not Applicable,Recruiting,Interventional,Stroke Patients; CPAP; OSA - Obstructive Sleep Apnea,CPAP device; CPAP technical support; Phone follow-up for adherence feedback and self-management skills; myAir; Tailored messages; Written Materials; Motivational Enhancement Therapy (MET),,University of Washington,"National Heart, Lung, and Blood Institute (NHLBI)",250,2025-01-15,2028-05-05,United States,No,https://clinicaltrials.gov/study/NCT06722755
NCT06728774,"Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits, w/ Joren Adams",Not Applicable,Recruiting,Interventional,Major Depressive Disorder (MDD); Cognitive Dysfunction,Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD); Goal-focused Supportive Contact,,Portland VA Medical Center,Oregon Health and Science University,24,2025-05-01,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT06728774
NCT06748872,"EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a",Phase 1,Not yet recruiting,Interventional,Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer; Soft Tissue Sarcoma (STS); Myxoid Liposarcoma; Synovial Sarcoma,Lymphodepletion; TCR-T cells (MDG1015),,Medigene AG,,55,2025-07-01,2042-08-01,United States,No,https://clinicaltrials.gov/study/NCT06748872
NCT06797999,"A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma,Antibody-drug conjugate (ADC),,Adcendo ApS,,270,2025-06-05,2029-02-27,Belgium; France; Germany; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06797999
NCT06798012,"A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)",Phase 2,Recruiting,Interventional,Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP),TAK-411,,Takeda,,36,2025-05-14,2028-06-08,Canada; Colombia; United States,No,https://clinicaltrials.gov/study/NCT06798012
NCT06801678,Refractive Outcomes Utilizing Two SS-OCT Biometers for IOL Power Calculations,,Recruiting,Observational,Cataract,,,The Eye institute of Utah,Alcon Research,50,2025-01-09,2025-02-22,United States,No,https://clinicaltrials.gov/study/NCT06801678
NCT06876740,Project Safe Guard-Trauma (PSG-T): A Randomized Controlled Trial of Counseling to Promote a Secure Home Environment,Not Applicable,Recruiting,Interventional,PTSD; Firearm Injury; Suicide Prevention; Firearm Safety,Project Safe Guard - Trauma; Project Safe Guard,,"University of Colorado, Denver",,168,2025-05-15,2028-09-14,United States,No,https://clinicaltrials.gov/study/NCT06876740
NCT06884618,"A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)",Phase 1,Recruiting,Interventional,Neoplasms,RO7673396,,Hoffmann-La Roche,,345,2025-04-30,2029-05-25,Australia; Canada; China; Hong Kong; New Zealand; Singapore; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06884618
NCT06886152,Transcutaneous Spinal Stimulation and Gait Training to Improve Mobility and Motor Control in Individuals With Traumatic Brain Injury,Not Applicable,Not yet recruiting,Interventional,Traumatic Brain Injury; Traumatic Brain Injury (TBI); Hemiplegia and Hemiparesis,Transcutaneous Spinal Cord Stimulation; Sham,,Kessler Foundation,Shirley Ryan AbilityLab,30,2025-09-01,2028-09-01,United States,No,https://clinicaltrials.gov/study/NCT06886152
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06935370,"EASi-HF Reduced - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40%",Phase 3,Recruiting,Interventional,Heart Failure,vicadrostat; empagliflozin; Placebo,,Boehringer Ingelheim,,4200,2025-05-20,2029-02-22,Argentina; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Romania; Saudi Arabia; Serbia; Slovakia; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06935370
NCT06946225,"A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)",Phase 1,Recruiting,Interventional,Cutaneous Melanoma; Synovial Sarcoma,IMA203; mRNA-4203,,"Immatics US, Inc.","ModernaTX, Inc.",15,2025-07-25,2029-08-05,United States,No,https://clinicaltrials.gov/study/NCT06946225
NCT06953687,Implementing and Evaluating a Patient-Centered PTSD Treatment Program for Military Personnel,Not Applicable,Recruiting,Interventional,Post Traumatic Stress Disorder PTSD,Prolonged Exposure Therapy; Cognitive Processing Therapy; Written Exposure Therapy; Shared Decision Making (SHARE),,The University of Texas Health Science Center at San Antonio,United States Department of Defense,200,2025-05-09,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT06953687
NCT06970301,"A Single-center, Placebo-controlled, Participant-blind, Investigator-blind, Randomized, Multiple Ascending Dose in Titration Study to Assess The Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants",Phase 1,Recruiting,Interventional,Healthy Study Participants,glovadalen; Placebo,,UCB Biopharma SRL,,32,2025-04-28,2026-05-04,United States,No,https://clinicaltrials.gov/study/NCT06970301
NCT07049848,"SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma",Phase 2,Recruiting,Interventional,Soft Tissue Sarcoma,Atezolizumab; Doxorubicin Hydrochloride,,M.D. Anderson Cancer Center,"Genentech, Inc.",50,2025-09-11,2030-01-01,United States,No,https://clinicaltrials.gov/study/NCT07049848
NCT07055854,Virtual Mindful After Cancer Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors,Phase 1,Not yet recruiting,Interventional,Gynecologic Cancers; Breast Cancer,Mindful After Cancer Program,,Oregon State University,National Cancer Institute (NCI),60,2025-08-05,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT07055854
NCT07058064,WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring),Not Applicable,Recruiting,Interventional,Lymphoma; Sarcoma,Electrocardiogram; Echocardiogram; LVEF echocardiogram; Apple Watch; Biospecimen collection; Questionnaires; Cardio-pulmonary exercise test; 6 minute walk test; Grip strength test,,Mayo Clinic,,250,2025-07-18,2029-06-29,United States,No,https://clinicaltrials.gov/study/NCT07058064
NCT07069517,"Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD: A Randomized Controlled Trial",Not Applicable,Recruiting,Interventional,Insomnia; PTSD - Post Traumatic Stress Disorder; Nightmares,Cognitive-Behavioral Therapy for Insomnia (CBTi); Cognitive Behavioral Therapy for Nightmares (CBTn); Written Exposure Therapy (WET); Sleep Hygiene,,Palo Alto Veterans Institute for Research,"The University of Texas Health Science Center at San Antonio; University of Arizona; NDRI-USA, Inc.",160,2025-12-02,2028-12-01,United States,No,https://clinicaltrials.gov/study/NCT07069517
